Literature DB >> 27448749

IL-17 Responses Are the Dominant Inflammatory Signal Linking Inverse, Erythrodermic, and Chronic Plaque Psoriasis.

Xianying Xing1, Yun Liang1, Mrinal K Sarkar1, Liza Wolterink1, William R Swindell1, John J Voorhees1, Paul W Harms2, Joanne M Kahlenberg3, Andrew Johnston1, Johann E Gudjonsson4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27448749      PMCID： PMC5123949          DOI： 10.1016/j.jid.2016.07.008

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  11 in total

1.  IκBζ is a key driver in the development of psoriasis.

Authors:  Claus Johansen; Maike Mose; Pernille Ommen; Trine Bertelsen; Hanne Vinter; Stephan Hailfinger; Sebastian Lorscheid; Klaus Schulze-Osthoff; Lars Iversen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

2.  Infectious complications of erythrodermic psoriasis.

Authors:  M S Green; J H Prystowsky; S R Cohen; J I Cohen; M G Lebwohl
Journal:  J Am Acad Dermatol       Date:  1996-05       Impact factor: 11.527

Review 3.  Pustular and erythrodermic psoriasis.

Authors:  J H Prystowsky; P R Cohen
Journal:  Dermatol Clin       Date:  1995-10       Impact factor: 3.478

4.  Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation.

Authors:  Misha Rosenbach; Sylvia Hsu; Neil J Korman; Mark G Lebwohl; Melodie Young; Bruce F Bebo; Abby S Van Voorhees
Journal:  J Am Acad Dermatol       Date:  2009-08-08       Impact factor: 11.527

Review 5.  Psoriasis inversa: A separate identity or a variant of psoriasis vulgaris?

Authors:  Silje Haukali Omland; Robert Gniadecki
Journal:  Clin Dermatol       Date:  2015-04-08       Impact factor: 3.541

6.  Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients.

Authors:  A S Boyd; A Menter
Journal:  J Am Acad Dermatol       Date:  1989-11       Impact factor: 11.527

7.  Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.

Authors:  H Saeki; H Nakagawa; T Ishii; Y Morisaki; T Aoki; P-Y Berclaz; M Heffernan
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-10-30       Impact factor: 6.166

8.  T(H)17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26.

Authors:  Stephan Meller; Jeremy Di Domizio; Kui S Voo; Heike C Friedrich; Georgios Chamilos; Dipyaman Ganguly; Curdin Conrad; Josh Gregorio; Didier Le Roy; Thierry Roger; John E Ladbury; Bernhard Homey; Stanley Watowich; Robert L Modlin; Dimitrios P Kontoyiannis; Yong-Jun Liu; Stefan T Arold; Michel Gilliet
Journal:  Nat Immunol       Date:  2015-07-13       Impact factor: 25.606

9.  Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients.

Authors:  William R Swindell; Andrew Johnston; John J Voorhees; James T Elder; Johann E Gudjonsson
Journal:  BMC Genomics       Date:  2013-08-01       Impact factor: 3.969

10.  Modulation of epidermal transcription circuits in psoriasis: new links between inflammation and hyperproliferation.

Authors:  William R Swindell; Andrew Johnston; Xianying Xing; John J Voorhees; James T Elder; Johann E Gudjonsson
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240
View more
  9 in total

Review 1.  Psoriasis: Past, Present, and Future.

Authors:  Allison C Billi; Johann E Gudjonsson; John J Voorhees
Journal:  J Invest Dermatol       Date:  2019-11       Impact factor: 8.551

2.  IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation.

Authors:  Xinhui Ni; Yi Xu; Wang Wang; Baida Kong; Jian Ouyang; Jiwei Chen; Man Yan; Yawei Wu; Qi Chen; Xinxin Wang; Hongquan Li; Xiaoguang Gao; Hongquan Guo; Lian Cui; Zeyu Chen; Yuling Shi; Ronghui Zhu; Wei Li; Tieliu Shi; Lin-Fa Wang; Jinling Huang; Chen Dong; Yuping Lai
Journal:  Nat Immunol       Date:  2022-10-21       Impact factor: 31.250

Review 3.  Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances.

Authors:  Shuai Shao; Gang Wang; Emanual Maverakis; Johann E Gudjonsson
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

4.  Comparison of Immune and Barrier Characteristics in Scalp and Skin Psoriasis.

Authors:  Krisztián Gáspár; Adrienn Jenei; Ahmad Khasawneh; Barbara Medgyesi; Zsolt Dajnoki; Eszter Anna Janka; Imre Lőrinc Szabó; Zoltán Hendrik; Gábor Méhes; Andrea Szegedi; Anikó Kapitány
Journal:  Acta Derm Venereol       Date:  2020-07-02       Impact factor: 3.875

Review 5.  Digestive system in psoriasis: an update.

Authors:  Daniel Pietrzak; Aldona Pietrzak; Dorota Krasowska; Andrzej Borzęcki; Kinga Franciszkiewicz-Pietrzak; Beata Polkowska-Pruszyńska; Maja Baranowska; Kristian Reich
Journal:  Arch Dermatol Res       Date:  2017-09-13       Impact factor: 3.017

6.  Signs of innate immune activation and premature immunosenescence in psoriasis patients.

Authors:  Liisi Šahmatova; Elena Sügis; Marina Šunina; Helen Hermann; Ele Prans; Maire Pihlap; Kristi Abram; Ana Rebane; Hedi Peterson; Pärt Peterson; Külli Kingo; Kai Kisand
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

Review 7.  Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases.

Authors:  Thomas Litman
Journal:  APMIS       Date:  2019-05       Impact factor: 3.205

Review 8.  Low-Density Granulocytes in Immune-Mediated Inflammatory Diseases.

Authors:  Xin Ning; Wen-Ming Wang; Hong-Zhong Jin
Journal:  J Immunol Res       Date:  2022-01-31       Impact factor: 4.818

9.  Evidence for biochemical barrier restoration: Topical solenopsin analogs improve inflammation and acanthosis in the KC-Tie2 mouse model of psoriasis.

Authors:  Jack L Arbiser; Ron Nowak; Kellie Michaels; Yuliya Skabytska; Tilo Biedermann; Monica J Lewis; Michael Y Bonner; Shikha Rao; Linda C Gilbert; Nabiha Yusuf; Isabella Karlsson; Yi Fritz; Nicole L Ward
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.